CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

Cyclin D1(-) mantle cell lymphomas (MCLs) are not well characterized, in part because of the difficulties in their recognition. SOX11 has been identified recently as a reliable biomarker of MCL that is also expressed in the cyclin D1(-) variant. We investigated 40 lymphomas with MCL morphology and immunophenotype that were negative for cyclin D1 expression/t(11;14)(q13;q32) but positive for SOX11. These tumors presented clinically with generalized lymphadenopathy, advanced stage, and poor outcome (5-year overall survival, 48%). Chromosomal rearrangements of the CCND2 locus were detected in 55% of the cases, with an IG gene as partner in 18 of 22, in particular with light chains (10 IGK@ and 5 IGL@). No mutations in the phosphorylation motifs of CCND1, CCND2, or CCND3 were detected. The global genomic profile and the high complexity of the 32 cyclin D1(-) SOX11(+) MCL patients analyzed by copy number arrays were similar to the conventional cyclin D1/SOX11 MCL. 17p deletions and high Ki67 expression conferred a significantly worse outcome for the patients. This comprehensive characterization of a large series of cyclin D1(-) MCL patients indicates that these tumors are clinically and biologically similar to the conventional cyclin D1(+) MCL and provides a basis for the proper identification and clinical management of these patients.

[1]  L. Colomo,et al.  SOX11 is useful in differentiating cyclin D1‐positive diffuse large B‐cell lymphoma from mantle cell lymphoma , 2012, Histopathology.

[2]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[3]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[4]  K. Fu,et al.  Cyclin D1-negative Blastoid Mantle Cell Lymphoma Identified by SOX11 Expression , 2012, The American journal of surgical pathology.

[5]  R. Warnke,et al.  In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior , 2012, Haematologica.

[6]  M. Dreyling,et al.  Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. , 2011, Blood.

[7]  A. Rosenwald,et al.  The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.

[8]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[9]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[10]  A. Feldman,et al.  CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. , 2011, Cancer genetics.

[11]  L. Staudt,et al.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.

[12]  Lin He,et al.  mir-17-92, a cluster of miRNAs in the midst of the cancer network. , 2010, The international journal of biochemistry & cell biology.

[13]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[14]  X. Troussard,et al.  Waved aCGH: to smooth or not to smooth , 2010, Nucleic acids research.

[15]  Yasodha Natkunam,et al.  Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes , 2009, Modern Pathology.

[16]  W. Klapper,et al.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR , 2009, Haematologica.

[17]  Elin Gustavsson,et al.  Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma , 2009, Haematologica.

[18]  L. Staudt,et al.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.

[19]  A. Rosenwald,et al.  MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. , 2009, Cancer research.

[20]  R. Bellazzi,et al.  Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood , 2009, Human Genetics.

[21]  Xavier Estivill,et al.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. , 2009, Blood.

[22]  H. Pospíšilová,et al.  Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. , 2008, Blood.

[23]  L. de Leval,et al.  Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. , 2008, Blood.

[24]  Karin Jirström,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only. , 2006 .

[25]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[26]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Weisenburger,et al.  A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.

[28]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[29]  H. Tagawa,et al.  A microRNA cluster as a target of genomic amplification in malignant lymphoma , 2005, Leukemia.

[30]  L. Staudt,et al.  Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling , 2005 .

[31]  F Solé,et al.  Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. , 2001, Blood.

[32]  A. Rosenwald,et al.  Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.

[33]  Shigeo Nakamura,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma , 2000 .

[34]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.